Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Posaconazole - Merck & Co

Next Previous
Drug Profile

Posaconazole - Merck & Co

Alternative Names: IV posaconazole; MK-5592; NOXAFIL; Noxafil; Posaconazole oral suspension; Posaconazole SP; Posaconazole tablet; Posanol; SCH 056592; SCH 56592; Spriafil

Latest Information Update: 10 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co; MSD China; Schering-Plough
  • Class Antifungals; Fluorobenzenes; Furans; Ketones; Piperazines; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors; Cytochrome P-450 enzyme system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Invasive bronchopulmonary aspergillosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Candidiasis; Invasive bronchopulmonary aspergillosis; Mycoses; Oropharyngeal candidiasis
  • Phase II Chagas disease

Most Recent Events

  • 18 Dec 2023 Merck Sharp & Dohme completes the phase II MK-5592-104 trial in Invasive bronchopulmonary aspergillosis in Belgium, Greece, Hungary, Italy, Israel, Mexico, Peru, Russia, South Korea, and in USA (NCT04218851)
  • 11 May 2022 Preregistration for Invasive bronchopulmonary aspergillosis in China (PO) (Merck pipeline, May 2022)
  • 11 May 2022 Preregistration for Mycoses in China (IV) (Merck pipeline, May 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top